#China #Shanghai #Harbour BioMed #Immunology #Antibody Technology

Harbour BioMed Reports 2025 Interim Results

On August 27, 2025, Harbour BioMed (HKEX: 02142), a global leader in biopharmaceuticals specializing in novel antibody therapeutics, announced its interim results for the first half of the year ending June 30, 2025. With a commitment to advancing healthcare through the discovery and development of innovative treatments, the company reported substantial growth across multiple metrics.

Key Financial Metrics

Harbour BioMed’s financial results displayed impressive achievements: the total revenue reached approximately $101.3 million, marking a phenomenal 327% increase from the previous year. In addition, net profit surged to around $73 million, a staggering increase of 51 times compared to the same period in 2024. John Jingsong Wang, the Founder and CEO of Harbour BioMed, expressed pride in these accomplishments, emphasizing that they showcase the resilience and forward momentum of the firm.

The company's robust cash reserves, totaling approximately $320 million—a 92% increase from the end of the previous year—further underline its strengthening position in the market.

Strategic Partnerships and Collaborations

A cornerstone of Harbour BioMed's sustained growth has been its diversified business model that embraces licensing collaborations and strategic partnerships. The innovation-centric approach has culminated in the development of their unique Harbour Mice® platform, enabling the advancement of cutting-edge antibody therapeutics.

Throughout the first half of 2025, Harbour BioMed achieved several pivotal milestones: expanding collaborations with renowned global pharmaceutical companies and academic institutions. This strategy has not only propelled its clinical-stage products but has also enhanced its portfolio of next-generation therapies.

Advancing Innovative Therapies

Among the notable products in development, Batoclimab (HBM9161) stands out as the first anti-FcRn monoclonal antibody, successfully completed Phase I to pivotal trials in China. This fully human monoclonal antibody shows promise in treating a range of autoimmune diseases. The results from the Phase III pivotal clinical trial, published in JAMA Neurology, corroborated its efficacy and safety.

Other significant clinical-stage projects include HBM9378, targeting thymic stromal lymphopoietin (TSLP), which is crucial for many immunological conditions. Following IND approval for moderate-to-severe asthma, the company has plans for further clinical trials, indicating a proactive approach to therapeutic development.

Porustobart (HBM4003), another trailblazing therapy derived from the HCAb Harbour Mice® platform, is set to enable enhanced treatment for multiple solid tumors. Initial data from monotherapy trials and combination trials with PD-1 inhibitors exhibit positive results, paving the way for more extensive clinical applications.

Future Prospects

With its sustained growth trajectory, Harbour BioMed is focused on continuing innovation. In March 2025, the company pioneer launched Élancé Therapeutics, aiming to tackle obesity through advanced bispecific antibody technology. These initiatives exemplify Harbour BioMed's dedication to expanding its treatment pipeline to encompass complex conditions such as neurodegenerative disorders and metabolic diseases.

As Harbour BioMed looks towards future developments, it aims to capitalize on its unique position within the global biopharmaceutical landscape, further enhancing its innovation ecosystem. According to Wang, the ultimate goal remains clear: “Delivering better treatment options for patients worldwide.”

With its commitment to innovative biopharmaceutical advancements and strategic collaborations, Harbour BioMed is optimally positioned to thrive in an ever-evolving healthcare landscape. As they continue to cross industry boundaries, the company is sure to remain a significant player in the biopharmaceutical sector well into 2025 and beyond.